Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA methylation and Panel sequencing for pancreatic neuroendocrine carcinomas (PanNECs) and pancreatic neuroendocrine tumors (PanNETs)

ABSTRACT: Pancreatic Neuroendocrine Neoplasms (PanNENs) are two subclasses: the well-differentiated, low to high-grade Pancreatic Neuroendocrine Tumors (PanNETs) and the poorly-differentiated, high-grade Pancreatic Neuroendocrine Carcinomas (PanNECs). DNA methylation and sequencing was performed for 57 PanNEN samples to decipher distinct methylation profiles separating PanNENs. Our study provides a robust and clinically applicable method to clearly distinguish PanNECs from PanNETG3s and improve patient stratification.

PROVIDER: EGAS00001005731 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

Project description:The grade of pancreatic neuroendocrine tumors principally influences therapy. Grading is currently done by the histological examination of biopsy samples, which is an invasive and time-consuming method. We performed an NGS on FFPE tumor tissue samples to find microRNAs that show a significant difference in expression according to grade, thus could be suitable for grade determination.

2024-08-02 | GSE265752 | GEO

Proteogenomic characterization of pancreatic neuroendocrine tumor

Project description:To characterize pancreatic neuroendocrine tumor at protein level, we performed mass spectromery-based proteome analysis using clinical FFPE tissue samples.

2024-07-10 | PXD034571 | Pride

DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association

Project description:This study evaluate the methylation profile of 84 clinically sporadic pancreatic neuroendocrine tumors (PanNETs) with associated clinical and genomic information. We identified three subgroups of PanNETs, termed T1, T2 and T3, with distinct patterns of methylation. The T1 subgroup was enriched for functional tumors and ATRX, DAXX and MEN1 wild-type genotypes. The T2 subgroup contained tumors with mutations in ATRX, DAXX and MEN1 and recurrent patterns of chromosomal losses in half of the genome with no association between regions with recurrent LOH and methylation levels. T2 tumors were larger and had lower methylation in the MGMT gene body, which showed positive correlation with gene expression. The T3 subgroup harboured mutations in MEN1 with recurrent LOH of chromosome 11, was enriched for grade G1 tumors and showed histological parameters associated with better prognosis. Our results suggest a role for methylation in both driving tumorigenesis and potentially stratifying prognosis in PanNETs. These set of normal adjacent pancreata was compared to ICGC pancreatic neuroendocrine tumour methylation. We identified CpG sites located in promoter regions with low levels of methylation (beta value <0.3) in all normal adjacent pancreata and from those selected the most variable probes with a standard deviation >0.20 of DNA methylation levels across all tumors to identify sub-groups.

2021-02-16 | GSE149395 | GEO

MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

Project description:MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

| PRJNA1104139 | ENA

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms

Project description:Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically heterogeneous neoplasms. We used quantitative global proteomic analysis on 40 PNENs to compliment paired transcriptome data.

2021-11-30 | PXD024175 | Pride

RHAMMB promotes metastasis of pancreatic neuroendocrine tumor

Project description:Analysis of molecular mechanisms by which RHAMMB promote metastasis of pancreatic neuroendocrine tumor.

2024-04-16 | GSE200497 | GEO

Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm

Project description:Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm

| PRJNA1004639 | ENA

Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm

Project description:Pancreatic neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) are rare pancreatic malignant tumors, and comprehensive gene analyses are scarce. In this study, six NECs and six MiNENs were collected, immunohistochemistry for synaptophysin, chromogranin A, INSM1, Ki-67, and Rb was conducted, and KRAS mutational status was examined. Among these cases, comprehensive gene expression analysis of oncogene pathways using nCounter® were performed with six NECs and four MiNENs, and those data were compared with that of three pancreatic ductal adenocarcinomas (PDACs), with that of three normal pancreatic ducts, and with each other. By dividing NEC and MiNEN cases into KRAS-mutated group and KRAS-wild group, the difference of clinicopathological data and gene expression profiling data were examined between the two groups. Compared to the data of normal pancreatic epithelium, all 13 cancer-related pathways were upregulated in PDAC, MiNEN, and NEC group with more upregulation in this order. Compared to the data of PDAC, genes of DNA Damage repair pathway was most upregulated both in NECs and MiNENs. Regarding the difference between KRAS-mutated and KRAS-wild groups, several genes were differentially expressed between the two, where MMP7 was the upregulated gene with highest p-value and NKD1 was the downregulated gene with highest p-value in KRAS-mutated group. From the extent of upregulation of 13 pathways, MiNEN was considered more progressed stage than PDAC, and NEC was considered more progressed than MiNEN. From the comparison of KRAS-mutated and KRAS-wild NECs and MiNENs, several differentially expressed genes were identified in this study.

2024-08-11 | GSE240700 | GEO

MUC1-C DICTATES NEUROENDOCRINE LINEAGE SPECIFICATION IN PANCREATIC DUCTAL ADENOCARCINOMAS

Project description:MUC1-C drives neuroendocrine lineage plasticity in pancreatic adenocarcinomas

2021-08-13 | GSE181961 | GEO

Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer

Project description:Pancreatic neuroendocrine tumors (pNETs) are uncommon cancers arising from pancreatic islet cells. Here we report analysis of gene mutation, copy number and RNA expression of 57 sporadic well-differentiated pNETs.

| EGAS00001003038 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data